PERMAX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PERMAX (PERMAX).
Dopamine D1/D2 receptor agonist; also activates α2-adrenergic and serotonin receptors, reducing prolactin secretion.
| Metabolism | Hepatic (CYP3A4, CYP1A2); extensive first-pass metabolism. |
| Excretion | Renal: ~50% unchanged drug; biliary/fecal: ~40% as metabolites and parent drug; total clearance approximates hepatic blood flow. |
| Half-life | Terminal elimination half-life: 27 hours (range 24-30 hours) in healthy adults; significantly prolonged in renal impairment (up to 100+ hours in ESRD), requiring dose adjustment. |
| Protein binding | ~90% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vd: 6-8 L/kg (central compartment ~0.5 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Oral: ~50% (range 30-70%) due to first-pass hepatic metabolism; food does not significantly affect absorption. |
| Onset of Action | Oral: 1-2 hours to clinical effect (improvement in Parkinsonian symptoms); peak effect at 2-4 hours. |
| Duration of Action | Oral: 5-8 hours for motor response; may be longer in some patients due to long half-life. Clinical benefit may extend beyond serum half-life due to receptor binding. |
Initial: 0.05 mg orally once daily; titrate by 0.05-0.1 mg/day every 2-3 days; usual therapeutic dose: 0.1-0.5 mg three times daily; maximum: 1.5 mg three times daily.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 50%; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: use with caution, consider dose reduction; Child-Pugh Class B or C: contraindicated. |
| Pediatric use | Safety and efficacy not established; no approved pediatric dosing. |
| Geriatric use | Start at low end of dosing range (0.05 mg once daily); titrate slowly due to increased risk of hypotension and hallucinations. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PERMAX (PERMAX).
| Breastfeeding | Pergolide suppresses lactation by inhibiting prolactin secretion. It is excreted in human breast milk; M/P ratio not established. Contraindicated in breastfeeding women due to potential for dopamine receptor stimulation in infant and suppression of lactation. |
| Teratogenic Risk | Pergolide (PERMAX) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity, but no adequate, well-controlled studies in pregnant women exist. First trimester: theoretical risk due to dopamine agonist activity; second/third trimester: limited data, risk of postpartum hemorrhage due to ergot alkaloid properties. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to pergolide; ergot alkaloid allergy; history of cardiac valvulopathy.
| Precautions | May cause valvular heart disease; fibrotic complications (pleural, pericardial, peritoneal); sudden sleep onset; orthostatic hypotension; hallucinations; impulse control disorders; dopamine agonist withdrawal syndrome. |
Loading safety data…
| Fetal Monitoring | Monitor for signs of valvular heart disease (echocardiography) and pleural/pulmonary fibrosis. In pregnancy, monitor fetal growth via ultrasound if prolonged use. Assess maternal blood pressure and signs of ergotism (vasospasm, ischemia). |
| Fertility Effects | Pergolide can restore fertility in hyperprolactinemic patients by normalizing prolactin levels. In normoprolactinemic individuals, it may impair fertility by disrupting dopamine-prolactin axis. Ergot alkaloid structure may cause uterine contractions and implantation interference. |